A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated
dose of the combination of carfilzomib and cyclophosphamide with dexamethasone (Car-Cy-Dex)
prior to autologous stem cell transplant (ASCT) in patients with newly diagnosed transplant
eligible multiple myeloma.